Introduction: Who Should Undergo Diagnostics

Adenosquamous carcinoma of the lung is a relatively uncommon type of non-small cell lung cancer (NSCLC), which means it has features of both adenocarcinoma and squamous cell carcinoma. When caught at stage 0, also known as carcinoma in situ, the cancer is confined to the top lining of the lung or the airway tubes. It has not yet spread to other parts of the lung or to distant organs.^[1]

Stage 0 lung cancer is rarely discovered because it often does not cause noticeable symptoms in its earliest phase. Most people at this stage do not feel sick, which makes screening and diagnostic testing especially important for those at high risk. People who should consider undergoing lung cancer diagnostics include current or former smokers, individuals exposed to harmful substances like asbestos or radon, and anyone with a family history of lung cancer. Screening is especially recommended for people aged 50 and older who have a significant smoking history.^[1]

If you experience persistent symptoms such as a cough that does not go away, coughing up blood, shortness of breath, chest pain, hoarseness, or unexplained weight loss, it is advisable to seek medical attention promptly. Even though these symptoms are more common in advanced stages, they can sometimes appear early and warrant investigation.^[1]

Smoking remains the leading risk factor for adenosquamous carcinoma, as it is strongly linked to both adenocarcinoma and squamous cell components. However, exposure to other cancer-causing agents such as asbestos, radon, and secondhand smoke also plays a role in the development of this disease.^[2] Understanding your risk factors can help you decide when to seek diagnostic testing.

Diagnostic Methods for Adenosquamous Cell Lung Cancer

Diagnosing adenosquamous cell lung cancer at stage 0 requires a combination of imaging tests and tissue analysis. Because the cancer is so small and localized at this stage, precise diagnostic tools are necessary to identify it and distinguish it from other lung conditions.

Imaging Tests

The first step in diagnosing lung cancer typically involves imaging tests that allow doctors to see inside the lungs and identify any abnormalities. A chest X-ray may be used as an initial screening tool, but it is not always sensitive enough to detect very early stage cancers. For this reason, doctors often turn to more advanced imaging techniques.^[1]

A computed tomography (CT) scan is one of the most important diagnostic tools for detecting early stage lung cancer. A CT scan uses X-rays taken from different angles to create detailed cross-sectional images of the lungs. This test can reveal small tumors or abnormal growths that might not be visible on a standard chest X-ray. Low-dose CT scans are commonly used for lung cancer screening in high-risk individuals because they provide clear images while minimizing radiation exposure.^[1]

Positron emission tomography (PET) scans may also be used, especially if doctors need to determine whether cancer has spread beyond the initial site. PET scans involve injecting a small amount of radioactive sugar into the bloodstream. Cancer cells, which use more energy than normal cells, absorb more of this substance and show up as bright spots on the scan. While PET scans are more commonly used for staging advanced cancers, they can provide additional information when needed.^[1]

Biopsy and Tissue Analysis

Imaging tests can suggest the presence of cancer, but only a biopsy can confirm the diagnosis. A biopsy involves taking a small sample of tissue from the suspicious area and examining it under a microscope. This is the definitive way to determine whether cancer is present and, if so, what type of cancer it is.^[2]

For lung cancer, several biopsy techniques may be used depending on the location and size of the tumor. Bronchoscopy is a common procedure where a thin, flexible tube with a camera on the end is inserted through the nose or mouth and down into the airways. This allows the doctor to see the inside of the airways and take tissue samples from suspicious areas. Bronchoscopy is particularly useful for tumors located in the airway lining, which is often the case with stage 0 lung cancer.^[1]

In some cases, doctors may perform a needle biopsy, where a thin needle is guided into the lung using CT imaging. The needle is used to extract a small piece of tissue for analysis. This technique is less invasive than surgical biopsy but still provides valuable diagnostic information.

Once the tissue sample is obtained, a pathologist (a doctor who specializes in diagnosing diseases by examining tissues) will study it under a microscope. Adenosquamous carcinoma is identified by the presence of both glandular cells (typical of adenocarcinoma) and flat, scale-like cells (typical of squamous cell carcinoma). This dual appearance is what defines this particular subtype of lung cancer.^[4]

Additional Diagnostic Tests

Beyond imaging and biopsy, other tests may be used to assess lung function and overall health. Pulmonary function tests measure how well the lungs are working, which helps doctors understand whether a patient can tolerate certain treatments, especially surgery. Blood tests may also be performed to check for general health markers and to rule out other conditions.^[1]

In some cases, doctors may use specialized procedures like endobronchial therapies, which involve looking inside the airways with a camera and treating small tumors directly. Techniques such as electrocautery (using electric current to destroy abnormal tissue), cryosurgery (freezing abnormal tissue), or photodynamic therapy (using light-activated drugs to kill cancer cells) may be used both for diagnosis and treatment of stage 0 tumors found in the airway lining.^[11]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or strategies for managing cancer. Patients with stage 0 adenosquamous cell lung cancer may be eligible to participate in clinical trials, especially those studying new ways to detect, treat, or prevent early stage lung cancer. To qualify for a clinical trial, patients must meet specific criteria, and diagnostic tests play a key role in determining eligibility.

Most clinical trials require detailed information about the patient’s diagnosis, including the type of cancer, its stage, and specific characteristics of the tumor. This means that all the standard diagnostic tests—imaging, biopsy, and pathology review—must be completed and documented. The results help researchers determine whether a patient fits the study’s criteria.^[2]

Biomarker testing is increasingly important in clinical trial qualification. Biomarkers are specific genes, proteins, or other substances in the body that can provide information about a person’s cancer. For non-small cell lung cancer, including adenosquamous carcinoma, doctors may test tumor tissue for certain genetic mutations or changes. These can include mutations in genes like EGFR, ALK, ROS1, and KRAS, which may make the cancer more responsive to targeted therapies.^[2]

While adenosquamous carcinoma is less commonly studied than pure adenocarcinoma or squamous cell carcinoma, some clinical trials specifically recruit patients with rare or mixed subtypes. Testing for biomarkers and other tumor characteristics helps match patients to the most appropriate studies. If a patient has a specific genetic mutation, they may be eligible for trials testing drugs that target that mutation.^[4]

In addition to tumor-specific tests, clinical trials often require general health assessments. This may include blood tests to check organ function, imaging to confirm the cancer has not spread, and lung function tests to ensure the patient can safely tolerate experimental treatments. Doctors may also review the patient’s medical history, current medications, and overall performance status (how well the patient can carry out daily activities).

Patients interested in clinical trials should discuss their options with their healthcare team. Doctors can help determine which trials are available and whether the patient’s diagnostic results meet the eligibility requirements. Participation in a clinical trial can offer access to cutting-edge treatments that are not yet widely available, and it also contributes to advancing medical knowledge that may help future patients.^[2]

It is important to note that clinical trials have strict protocols, and not every patient will qualify for every trial. However, the diagnostic information gathered during standard cancer evaluation often provides a strong foundation for determining eligibility. Patients should feel empowered to ask questions about clinical trials and explore whether this option might be right for them.